MLTXMoonLake Immunotherapeutics
- GlobeNewswire
MoonLake Announces Positive Topline Results from the Phase 3 IZAR-1 Trial of Sonelokimab in Psoriatic Arthritis Demonstrating Significant Improvements Across all Clinical Endpoints, and Reports Second Quarter 2026 Financial Results
Phase 3 IZAR-1 trial in bio-naïve patients met all clinical endpoints at Week 16 for 60 mg sonelokimabThe primary endpoint of ACR50 was met with a high response of 42.1% for sonelokimab’s 60 mg with induction, and ...
- Analyst Upgrades
HC Wainwright & Co. Reiterates Buy on MoonLake, Maintains $45 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates MoonLake with a Buy and maintains $45 price target. ...
- Analyst Upgrades
Leerink Partners Maintains Outperform on MoonLake, Raises Price Target to $29
Leerink Partners analyst Thomas Smith maintains MoonLake with a Outperform and raises the price target from $24 to $29. ...
- GlobeNewswire
MoonLake Immunotherapeutics Announces Pricing of Upsized $200 Million Public Offering
ZUG, Switzerland, June 23, 2026 – MoonLake Immunotherapeutics (NASDAQ:MLTX) ("MoonLake"), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and joint diseases, ...
- GlobeNewswire
MoonLake Immunotherapeutics Announces Proposed Public Offering
ZUG, Switzerland, June 22, 2026 – MoonLake Immunotherapeutics (NASDAQ:MLTX) ("MoonLake"), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory skin and joint diseases, ...
- GlobeNewswire
MoonLake Announces Week 52 Results of Sonelokimab from its Phase 3 VELA Program in Hidradenitis Suppurativa and Confirms Investor Day on June 22, 2026
Results from the Phase 3 VELA clinical trials at Week 52 in adults with moderate-to-severe hidradenitis suppurativa (HS) demonstrate sonelokimab’s (SLK) potential best-in-class and best-in-disease profile, with ...
- Analyst Upgrades
BTIG Reiterates Buy on MoonLake, Maintains $30 Price Target
BTIG analyst Julian Harrison reiterates MoonLake with a Buy and maintains $30 price target. ...
- Analyst Upgrades
HC Wainwright & Co. Reiterates Buy on MoonLake, Maintains $45 Price Target
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates MoonLake with a Buy and maintains $45 price target. ...
- Analyst Upgrades
Needham Maintains Buy on MoonLake, Raises Price Target to $30
Needham analyst Serge Belanger maintains MoonLake with a Buy and raises the price target from $25 to $30. ...
- Analyst Upgrades
HC Wainwright & Co. Maintains Buy on MoonLake, Raises Price Target to $45
HC Wainwright & Co. analyst Raghuram Selvaraju maintains MoonLake with a Buy and raises the price target from $40 to $45. ...
- GlobeNewswire
MoonLake Immunotherapeutics Announces Positive Outcome from its Final Pre-BLA Meeting with the U.S. FDA and Reports First Quarter 2026 Financial Results
MoonLake conducted a positive final pre-BLA (Biologics License Application) meeting with the U.S. Food and Drug Administration (FDA), where MoonLake and the FDA aligned on submission plans and the label strategy for ...
- Analyst Upgrades
Insmed Drug Misses Primary Goal, Program Axed
Insmed halts HS program after CEDAR study miss; analysts cite trial challenges while focus shifts to Brinsupri and Arikayce growth drivers. ...
- Analyst Upgrades
BTIG Reiterates Buy on MoonLake, Maintains $30 Price Target
BTIG analyst Julian Harrison reiterates MoonLake with a Buy and maintains $30 price target. ...
- GlobeNewswire
MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting
Results from the Phase 3 VELA clinical trials in adults with moderate-to-severe hidradenitis suppurativa (HS) show that clinical responses continue to improve to Week 40, with 62% of patients treated with sonelokimab ...
- Analyst Upgrades
This APA Analyst Is No Longer Bearish; Here Are Top 2 Upgrades For Monday
Top Wall Street analysts upgraded APA Corp. & MoonLake Immunotherapeutics, see why & what other analysts think on our analyst ratings page. ...
- Analyst Upgrades
Wolfe Research Upgrades MoonLake to Outperform, Raises Price Target to $24
Wolfe Research analyst Andy Chen upgrades MoonLake from Underperform to Outperform and raises the price target from $12 to $24. ...
- Analyst Upgrades
Rothschild & Co Upgrades MoonLake to Buy, Raises Price Target to $40
Rothschild & Co analyst Qize Ding upgrades MoonLake from Neutral to Buy and raises the price target from $12 to $40. ...
- Analyst Upgrades
Clear Street Maintains Buy on MoonLake, Raises Price Target to $70
Clear Street analyst Kaveri Pohlman maintains MoonLake with a Buy and raises the price target from $45 to $70. ...
- Analyst Upgrades
RBC Capital Maintains Sector Perform on MoonLake, Raises Price Target to $13
RBC Capital analyst Brian Abrahams maintains MoonLake with a Sector Perform and raises the price target from $12 to $13. ...
- Analyst Upgrades
HC Wainwright & Co. Maintains Buy on MoonLake, Raises Price Target to $40
HC Wainwright & Co. analyst Raghuram Selvaraju maintains MoonLake with a Buy and raises the price target from $32 to $40. ...
- Analyst Upgrades
Needham Reiterates Buy on MoonLake, Maintains $25 Price Target
Needham analyst Serge Belanger reiterates MoonLake with a Buy and maintains $25 price target. ...
- Analyst Upgrades
Oppenheimer Maintains Outperform on MoonLake, Raises Price Target to $35
Oppenheimer analyst Andreas Argyrides maintains MoonLake with a Outperform and raises the price target from $30 to $35. ...
- GlobeNewswire
MoonLake Announces Positive Topline Results from its Phase 2 Clinical Trial of Sonelokimab in Axial Spondyloarthritis and Reports 2025 Financial Results
In the Phase 2 S-OLARIS clinical trial in axial spondyloarthritis (axSpA), sonelokimab (SLK) demonstrated clinically meaningful benefit with 80+% of patients achieving ASAS40 by Week 12Consistently, other clinical and ...
- Analyst Upgrades
RBC Capital Maintains Sector Perform on MoonLake, Raises Price Target to $12
RBC Capital analyst Brian Abrahams maintains MoonLake with a Sector Perform and raises the price target from $10 to $12. ...
- GlobeNewswire
ImageneBio Appoints Immunology Drug Development Veteran Dr. Ben Porter-Brown as Chief Medical Officer
Brings 20+ years of clinical development experience in autoimmune and inflammatory diseases, including OX40/OX40L program leadership Will build and lead Imagene's clinical organization and drive completion of the Phase ...